Compounds and compositions for treating hematological disorders

Inventors

Booher, Robert

Assignees

Curis Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10758518-B2

Patent

Publication Date

2020-09-01

Expiration Date


Abstract

The present invention provides methods of treating hematological disorders and solid malignant tumors, using substituted indazole compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and BCL-2 kinases.

Core Innovation

The disclosure provides cancer treatment methods that administer compound A together with venetoclax. Compound A is identified as an IRAK-4 inhibitor, and venetoclax is used as a BCL-2 inhibitor, specifically venetoclax (ABT-199). The methods are directed to treating Diffuse Large B-cell Lymphoma (DLBCL) in a subject, including activated B-cell-like DLBCL (ABC-DLBCL).

The document defines compound A using formulas (I)/(II)/(III) with extensive substituent definitions and includes specific exemplary structures, including Compound A. It further states variable definitions such as A, Y, R1–R3, m, n, and Z1/Z2, and it addresses stereoisomers and pharmaceutically acceptable salts. The described approach is framed as a conjoint administration of an IRAK-4 inhibitor with a BCL-2 inhibitor (venetoclax).

The disclosure states that the combination of compound A and venetoclax provides improved efficacy, including synergistic tumor growth inhibition, compared with either agent alone. It reports example in vivo data in ABC-DLBCL mouse xenograft models (including OCI-Ly10 and SU-DHL-2) showing tumor regression with compound A plus venetoclax. The summary further indicates tolerability as described in the document, and includes discussion of dosing regimens and re-dosing effects.

Claims Coverage

The provided independent claim covers a method of treating DLBCL by administering compound A (an IRAK-4 inhibitor) in conjunction with venetoclax (a BCL-2 inhibitor). The dependent claims further refine the targeted patient subgroup and the DLBCL subtype and include refinements related to comparative efficacy and administration timing.

Conjoint administration for DLBCL treatment

A method of treating Diffuse Large B-cell Lymphoma (DLBCL) in a subject, comprising administering compound A and venetoclax, wherein compound A is an IRAK-4 inhibitor.

MYD88 L265P subgroup selection

The method where the subject has an L265P mutation in MYD88.

Activated B-cell subtype DLBCL targeting

The method for an activated B-cell subtype of DLBCL that is an activated B-cell type DLBCL.

Improved efficacy versus separate administration

The method where co-administering compound A with venetoclax provides improved efficacy compared with administering compound A or venetoclax separately.

Simultaneous administration timing

The method performed by administering compound A and venetoclax simultaneously.

Venetoclax timing window relative to compound A

Administering venetoclax within about 5 minutes to about 168 hours before or after administration of compound A.

Across the independent claim and its dependents, the core coverage is a DLBCL treatment method using conjoint administration of an IRAK-4 inhibitor (compound A) with the BCL-2 inhibitor venetoclax, with dependent refinements including MYD88 L265P and activated B-cell DLBCL selection, comparative efficacy versus separate administration, and specific administration timing relationships.

Stated Advantages

Improved efficacy versus administering compound A or venetoclax separately.

Synergistic tumor growth inhibition.

Tumor regression in ABC-DLBCL mouse xenograft models with compound A plus venetoclax.

Documented Applications

Treating Diffuse Large B-cell Lymphoma (DLBCL) in a subject, including activated B-cell-like DLBCL (ABC-DLBCL), using conjoint administration of compound A and venetoclax.

In vivo evaluation in ABC-DLBCL mouse xenograft models, including OCI-Ly10 and SU-DHL-2, showing tumor regression with compound A plus venetoclax.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.